S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Final stage before digital money (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Final stage before digital money (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Final stage before digital money (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Final stage before digital money (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Final stage before digital money (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Final stage before digital money (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Final stage before digital money (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Final stage before digital money (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Forecast, Price & News

$3.76
-0.18 (-4.57%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$3.71
$4.10
50-Day Range
$2.86
$5.22
52-Week Range
$2.59
$22.80
Volume
79,000 shs
Average Volume
249,810 shs
Market Capitalization
$3.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KRBP stock logo

About Kiromic BioPharma (NASDAQ:KRBP) Stock

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

KRBP Stock News Headlines

Free A.I. Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Kiromic BioPharma Announces Reverse Stock Split
Free A.I. Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Kiromic BioPharma CEO Issues Letter to Stockholders
CTI BioPharma: Checking Back In
Kiromic BioPharma Arranges Up to $10 Million Financing
See More Headlines
Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

KRBP Company Calendar

Today
5/29/2023
Next Earnings (Estimated)
6/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRBP
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-34,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($8.91) per share

Miscellaneous

Free Float
907,000
Market Cap
$3.68 million
Optionable
Not Optionable
Beta
0.17

Key Executives

  • Mr. Pietro Bersani CPA (Age 55)
    J.D., CEO & Director
    Comp: $167.76k
  • Dr. Scott Dahlbeck M.D. (Age 61)
    Pharm.D., PharmD, Chief of Staff
    Comp: $442.12k
  • Mr. Daniel Clark (Age 34)
    Chief Financial Officer
  • Dr. Leonardo Mirandola Ph.D.
    Chief Scientific Officer
  • Dr. Michael Ryan Ph.D. (Age 56)
    Chief Bioinformatics Research Computing Officer













KRBP Stock - Frequently Asked Questions

How have KRBP shares performed in 2023?

Kiromic BioPharma's stock was trading at $5.4210 on January 1st, 2023. Since then, KRBP stock has decreased by 30.6% and is now trading at $3.76.
View the best growth stocks for 2023 here
.

When is Kiromic BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 2nd 2023.
View our KRBP earnings forecast
.

When did Kiromic BioPharma's stock split?

Shares of Kiromic BioPharma reverse split on the morning of Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

(KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager.

What is Kiromic BioPharma's stock symbol?

Kiromic BioPharma trades on the NASDAQ under the ticker symbol "KRBP."

Who are Kiromic BioPharma's major shareholders?

Kiromic BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (1.68%). Insiders that own company stock include Internati Maurizio Chiriva and Jerry A Schneider.
View institutional ownership trends
.

How do I buy shares of Kiromic BioPharma?

Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiromic BioPharma's stock price today?

One share of KRBP stock can currently be purchased for approximately $3.76.

How much money does Kiromic BioPharma make?

Kiromic BioPharma (NASDAQ:KRBP) has a market capitalization of $3.68 million. The company earns $-34,730,000.00 in net income (profit) each year or ($30.33) on an earnings per share basis.

How can I contact Kiromic BioPharma?

The official website for the company is www.kiromic.com. The company can be reached via phone at 832-968-4888 or via email at bus.dev@kiromic.com.

This page (NASDAQ:KRBP) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -